TROL

Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance

Both methicillin sensitive and methicillin resistant Staphylococcus aureus (MSSA, MRSA) can cause invasive and life-threatening infections such as osteomyelitis, septicemia, endocarditis, and pneumonia. Healthcare associated MRSA is of particular clinical importance because it is not only predictably cross resistant to all penicillins and cephalosporins, but is also typically resistant to mu...

Tight Glycemic Control in the ICU

The outcome of many illnesses for which patients are treated in intensive care units (ICUs) has not improved dramatically over the past decades, despite the development of high-tech monitors and sophisticated mechanical and pharmacological support of vital organ systems. Indeed, critically ill patients requiring intensive care for more than five day...

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

According to the American Diabetes Association, the total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. A chronic disease with no cure, diabetes is a group of diseases (including Type 1, Type 2, and gestational) marked by...

Optimizing Quality Control Data Management

Automation continues to gain importance in modern clinical laboratories in step with increasing test consolidation, rising demands from clinicians for rapid turnaround times, and an ever-mounting shortage of licensed medical technologists. Ultimately, the laboratories that implement high-quality automation solutions are better equipped to meet these modern demands....

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

-- Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company and A...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company (NYSE: BMY...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., announced today the publication of clinicaldata highlighting the ability of Glufast(R) (mitiglinide calciumhydrate) monotherapy, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublished in the Abstract Book for the American DiabetesAssociation 67th Annual Scien...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinicalresults from the first of five phase 3 studies with liraglutide -the once-daily human GLP-1 analogue. The 26-week study is part ofthe LEAD(TM) (Liraglutide Effect and Action in Diabetes) programmeand included 581 patients with type 2 diabetes inadequatelycontrolled by two of the most widely used oral antidiabetic drugs:metfor...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulationof Peramivir Supports Further Evaluation as Treatment for AcuteInfluenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. presented results from two Phase Iclinical studies of an intramuscular (i.m.) formulation ofperamivir at the Options for the Control of Influenza Conference inTor...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

* New data from 741-patient trial show those treated withPrexige experienced significantly smaller impact on blood pressurecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes in blood pressure can impactcardiovascular risk[2],[3] * Prexige approved in more than 50 countries and currently underreview in US for use in o...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

New data From 741-patient Trial Show Those Treated with LumiracoxibExperienced Significantly Smaller Impact on Blood Pressure Comparedto Ibuprofen EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients withosteoarthritis who also have controlled hypertension experienced aslight decrease in average daily blood pressure when treated withthe investigational selective COX-2 inhibitor lumi...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist

Findings Show Compliance with Medication Instructions butUnderscore Need for Improved Patient Communication, LifestyleManagement and More Healthcare Provider Efforts to Control ElevatedBlood Pressure NEW YORK, May 19, 2007 /PRNewswire/ -- Results of a surveyconducted by Harris Interactive(R) for the Hypertension EducationFoundation (HEF) were presented at the American Society ofHypertens...

King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control

BRISTOL, Tenn.--(BUSINESS WIRE)--May 19, 2007 - KingPharmaceuticals, Inc. (NYSE:KG) reported today that data from itsPhase III clinical trial evaluating Altace (ramipril) 20mg and thecombination of ALTACE 20mg and hydrochlorothiazide (HCT) 25mg werepresented this weekend at the American Society of Hypertension,Inc. (ASH) Twenty-Second Annual Scientific Meeting and Exposition(ASH 2007) in Ch...

Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data

Nine out of 10 non-diabetic patients treated withExforge achieved recommended blood pressure goals[1] Additional average decrease of 20 mmHg insystolic blood pressure observed in patients taking Exforge overreductions seen with previous monotherapy[1] Nearly 70% of those with high blood pressure notat treatme...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebocontrolled phase IIa study in patients suffering from house dustmite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos BiotechnologyAG (SWX:CYTN) reported today positive results from a multi-centreand placebo-controlled phase IIa study with different formulationsof CYT003-QbG10, an immunotherapeutic product can...

Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance

Support for Medical Use Approval and Insurance Coverage VariesGreatly for Different Medical Treatments ROCHESTER, N.Y. - April 30, 2007-- Most U.S. adults supportapproving the use of medical treatments and procedures that canimpact people's quality of life, including birth controltreatments, in-vitro fertilization, drugs to treat erectiledysfunction and improve memory and to...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of HypertensionTreatment Valsartan in Preventing Cardiovascular Events in JapanesePatients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinicaloutcomes of the JIKEI HEART Study, the large-scale clinical trialheaded by the Jikei University School of Medicine, was todaypublished in the internationally renowned medical journal TheLancet. The...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...

Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying to Control It Later

LONDON, April 12, 2007--The costs of eradicatingpoliomyelitis from the remaining infected countries, while high inthe short term, are much lower than the long term costs of tryingto control infections without eradication. And a recently developedmonovalent vaccine is almost three times more effective againsttype 1 poliomyelitis than an existing trivalent vaccine. These are...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

52-Week Trial Maintained Improvement in Personal and SocialPerformance COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ --Longer-term treatment with INVEGA(TM) (paliperidone)Extended-Release Tablets, a new once daily oral medication forschizophrenia, helped many patients effectively control theirsymptoms and maintain their improvements in personal and socialfunctioning....

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest SafetyProgram of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorablefindings of the investigational drug Cleviprex(TM) (clevidipine)compared to current intravenous antihypertensive agents incontrolling perioperative hypertension -- a potentially harmfulelevation in blood pressure j...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 -Cytos Biotechnology AG (SWX:CYTN) reported today positive resultsfrom a phase IIa study with CYT003-QbG10, an immunotherapeuticproduct candidate for the treatment of allergic diseases. The studyincluded 40 patients suffering from mild to moderate allergicrhinitis due to grass pollen allergy (hay fever). The trialinvestigated i...